Spot on comment Terry.
We - ahz shareholders have funded the Admedus vaccinne program all the way to this important juncture of results which will unfold in the next 6 months. From then on if the viral shedding drops off or disappears as planned there will be no shoratage of big pharmas bidding for a piece of the action.
If the vax actually fails to deliver we still have cardiocel and newer developments of the ADAPT technology making the company dollars through any unanticipated events like that.
Its hard to loose on ahz as a long term investment and its quite possible to also make an exceptional short term gain for those of that persuasion.
Fox
Vaxxas secures funding interest to see if professor Fraser utilizes nanopatch, page-81
-
- There are more pages in this discussion • 37 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.73 |
Change
-0.180(1.01%) |
Mkt cap ! $340.8M | |||
| Open | High | Low | Value | Volume |
| $18.00 | $18.10 | $17.73 | $50.92K | 2.848K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 62 | $17.73 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.87 | 3 | 2 |
View Market Depth
| Last trade - 14.04pm 16/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |